U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07393373) titled 'Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia' on Jan. 19.
Brief Summary: Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-selective tyrosine kinase inhibitor, in participants with Hypochondroplasia (HCH) who previously completed ACCEL 2/3, and potentially additional participants who completed ACCEL. Participants rolling over directly from the observational ACCEL study must have had at least a 6-month period of growth assessment in that study.
Study Start Date: April 21
Study Type:...